After Novo Nordisk (NVO) announced a company-wide transformation and said it intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, the company added: “The company-wide transformation comes with an expected DKK 8B in net one-off restructuring costs, including impairment charges. Restructuring costs of around DKK 9B will be incurred in the third quarter of 2025, countered by savings of around DKK 1B in the fourth quarter. Consequently, Novo Nordisk expects an estimated one-off negative impact of around 6 percentage points on full-year operating profit growth at CER in 2025 compared to the operating profit outlook issued 6 August.” The company now sees operating profit growth, or EBIT, at constant exchange rates of 4%-10%, versus the 10%-16% rate outlook communicated on August 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Strategic Restructuring Faces Uncertainty Amid Competitive Pressures
- Novo Nordisk Announces Major Transformation to Boost Growth in Diabetes and Obesity
- Novo Nordisk to reduce workforce by 9,000 positions
- Novo Nordisk Stock (NVO) Under Pressure as It Cuts Jobs and Lowers Outlook
- Bernstein upgrades Novo Nordisk with market ‘fully capitulated’